Contract Manufacturing Organizations (CMO) will reap the rewards as pharmaceutical production becomes increasingly globalized, according to a new report by business intelligence firm GBI Research.
The new report anticipates that the global CMO market will grow steadily due to the increased outsourcing of pharmaceutical production by Western pharmaceutical manufacturers to Asian countries. The availability of adequate numbers of current Good Manufacturing Practices and compliant manufacturing sites in Asia make India and China popular outsourcing destinations of choice for CMOs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze